Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Dana-Farber Cancer Institute
Summary
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Description
The goal of the PROMISE research study is to determine clinical/genomic alterations present in individuals with MGUS and SMM, who are diagnosed through screening of a high-risk population. We also seek to determine clinical/genomic/epigenetic and immune environmental predictors of progression to multiple myeloma in patients with MGUS and SMM.
Eligibility
- Age range
- 30+ years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Age ≥ 30 years * AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer. * Those over 18 are also eligible if they have 2 or more family members with a blood cancer Exclusion Criteria: \* • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy. • Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia First-degree re…
Interventions
- OtherSample of Blood
Collection of blood sample from participants
Location
- Dana Farber Cancer InstituteBoston, Massachusetts